Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PACMAN-AMI: Alirocumab in Acute MI
NCT03067844Phase 3Completed
- Sponsor
- Insel Gruppe
- Start
- Apr 2017
- Primary completion
- Oct 2021
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 3 trial of alirocumab in Coronary atherosclerosis (CAD), sponsored by Insel Gruppe. Started Apr 2017; status: completed.
02
Drugs
alirocumab
03
Conditions
Coronary atherosclerosis (CAD)
Beyond the preview
Go deeper on NCT03067844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03067844.